Chikungunya virus vaccine

The European Medicines Agency has suspended Valneva's Ixchiq chikungunya vaccine for elderly patients following reports of 17 serious adverse events, including two deaths, in people aged 62 to 89 years.

European Medicines Agency has suspended the use of Valneva's IXCHIQ chikungunya vaccine in people over 65 years old following reports of 17 serious adverse events, including two deaths, in elderly patients.

Valneva and LimmaTech have initiated two Phase 2 clinical trials for S4V2, the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis, a major global health threat.

• The EMA's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for Vyjuvek (beremagene geperpavec) to treat wounds in patients with dystrophic epidermolysis bullosa of all ages. • The Committee confirmed its previous marketing authorization recommendation for Leqembi (lecanemab) remains valid, while also expanding the indication for the chikungunya vaccine Ixchiq to include adolescents from 12 years. • Fabhalta received approval for treating adult patients with complement 3 glomerulopathy, and Deqsiga was recommended for approval in primary and secondary immunodeficiencies.

Valneva's IXCHIQ vaccine demonstrates a sustained 98.3% sero-response rate one year after single vaccination in adolescents, supporting potential label extension.